key: cord-0913454-2mzjydd3
authors: Revilla‐Nebreda, D.; Roncero‐Riesco, M.; Santos‐Briz, Á.; Medina‐Migueláñez, M.; Segurado‐Tostón, N.; Román‐Curto, C.
title: New‐onset acral lesions on hands after administration of mRNA‐1273 vaccine against SARS‐CoV‐2: clinical images and histopathological study of three cases
date: 2021-08-02
journal: J Eur Acad Dermatol Venereol
DOI: 10.1111/jdv.17553
sha: 38e34b2fc22a5807fcff957e4b0c9e348b2de4db
doc_id: 913454
cord_uid: 2mzjydd3

First approved vaccines against SARS-COV-2 (mRNA-1273 and BNT162b2) consists of Messenger Ribonucleic Acid (mRNA), encoding the SARS-CoV-2 spike protein, that penetrate cells and produce spike protein1 . In these vaccines' clinical trials, chilblain-like lesions were not reported2,3 ; however, the World Health Organization warned of the possible of appearance of chilblain-like lesions during SARS-CoV-2 vaccination campaign4 .

Clinical images of acral inflammatory lesions on the hands of the three patients. Patient 1 has itchy oedematous erythematous papules on the back of the hands and fingers (a1), mostly in the opposite hand to the vaccination arm (a2) and erythematous spots in palms (a3). The erythematous papules of this patient (a1, a2) could also be reminiscent of erythema multiforme-like lesions as well as chilblain-like lesions related to COVID-19. Patient 2 has a few similar lesions to the previous patient in the back of the hands. Patients 2 and 3 have itchy oedematous erythematous lesions in fingers (b1, b2, b3, c1, c2, c3). Most lesions in patients 2 and 3 appear on the opposite hand to the vaccination arm (b2, b3, c2, c3). set up. Second dose of SARS-CoV-2 vaccine was not contraindicated.

Two of the three patients are female and all three have ages ranging between 29 and 54 years. The three patients are hospital workers in SARS-CoV-2 free hospital zones. None of them have relevant medical history. All the three patients received mRNA-1273 SARS-CoV-2 vaccine and reported acral lesions on their hands between 3 and 10 days after the first dose. None had systemic symptoms. Both SARS-CoV-2 reverse transcriptase-polymerase chain reaction (RT-PCR) and SARS-CoV-2 antinucleocapsid antibodies CLIA test were negative in the three patients. Patient 2 and 3 had high titres for SARS-CoV-2 antispike antibodies (IgG). All patients received topical corticosteroids and lesions resolved in 15 days. The second dose of the vaccine had not complications or similar skin lesions. Clinical acral lesions are depicted and described in Fig. 1 . Histopathological study of the lesions of each patient revealed a chilblain-like histologic pattern (Fig. 2) .

We report a case-series of three patients with new-onset acral lesions on hands after administration of mRNA-1273 SARS-CoV-2 vaccine. These lesions are similar to SARS-CoV-2 chilblain-like lesions. Other aetiologies causing the lesions have been discarded given the normal values in laboratory screening tests. Although lesions appeared during the winter season, the temperatures in our district were not cold enough to think that could be simply idiopathic chilblain. Given that, no other recognizable cause for the lesions was found, and all three patients had a recent history of vaccination with mRNA-1273 SARS-CoV-2 vaccine, this is the most likely possible cause of these lesions. The three patients were able to complete vaccination doses without consequences. Figure 2 Histopathological images of acral inflammatory lesions on the hands in each of the three patients. Biopsies of the lesions revealed perivascular lymphocytic infiltrates with vascular damage (a1, a2, b1, b2, c1, c2) and red cell extravasation (a3, c3) in patients 1 and 3. The inflammatory infiltrate was mainly superficial but extended into the deep dermis (a1, a2, b1, b2, c1, c2), surrounding sweat glands in patient 2 (b3). Papillary dermal oedema was present in patients 1 and 2 (a2, c2). No interface dermatitis was evidenced in any patient. Lesions of all 3 patients presented a chilblain-like histology pattern.

Recently, isolated cases of chilblain-like after mRNA SARS-CoV-2 vaccines were reported, 5-9 but only one have histopathological study. 9 Some of the cases previously reported 6-9 describe acral lesions on hands, like in our three patients. This is the first case-series of acral lesions, similar to chilblainlike lesions, related to SARS-CoV-2 mRNA vaccines with clinical images and histopathological study. Besides, these are the first cases of acral lesions, similar to chilblain-like lesions after mRNA vaccines against SARS-CoV-2 reported in Spain.

Both SARS-CoV-2 mRNA vaccines produce SARS-CoV-2 spike protein in the human body, and this may directly or indirectly cause endotheliitis, which could lead to the appearance of acral inflammatory lesions or chilblain-like lesions. Further studies should be carried out over the pathophysiology of chilblainlike lesions related to COVID-19 and SARS-CoV-2 vaccines.

Dermatologists and other physicians should be aware of the possible of appearance of acral inflammatory lesions associated with SARS-CoV-2 vaccines. These lesions may be more frequent on hands. As chilblain-like lesions in COVID-19 patients are more frequent in children and young people, 10 more acral lesions or chilblain-like lesions associated with SARS-CoV-2 vaccines could be reported when vaccinating young people.

None.

None reported.

Revilla-Nebreda and Roncero-Riesco had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Revilla-Nebreda and Roncero-Riesco contributed equally. Concept and design: Revilla-Nebreda, Roncero-Riesco, Santos-Briz. Acquisition, analysis or interpretation of data: All authors. Drafting of the manuscript: Revilla-Nebreda, Roncero-Riesco, Medina-Miguel añez, Segurado-Tost on, Santos-Briz. Critical revision of the manuscript for important intellectual content: All authors. Statistical analysis: Not applicable. Obtained funding: Roncero-Riesco, Santos-Briz, Rom an-Curto. Administrative, technical or material support: All authors. Supervision: Revilla-Nebreda, Roncero-Riesco, Santos-Briz, Rom an-Curto. Other (diagnosis pathology): Santos-Briz.

Non-viral COVID-19 vaccine delivery systems

Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

COVID-19 vaccines: safety surveillance manual. World Health Organization

Cutaneous Reactions Reported after Moderna and Pfizer COVID-19 Vaccination: A Registry-Based Study of 414 Cases

Acral chilblain-like lesions following inactivated SARS-CoV-2 vaccination

Chilblain lesions after COVID-19 mRNA vaccine

BNT162b2 mRNA Covid-19 Vaccine-induced chilblain-like lesions reinforces the hypothesis of their relationship with SARS-CoV-2

New-onset chilblains in close temporal association to mRNA-1273 vaccination

Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases

The patients in this manuscript have given written informed consent to the publication of their case details.

We thank the patients for granting permission to publish this information. We also thank Borja Puertas-Martinez, MD, from Hematology Department, Complejo Asistencial Universitario de Salamanca; Pedro Revilla, PhD, from Misi on Biol ogica de Galicia of the Spanish National Research Council (CSIC); and Montse Charles-Harris, PhD, from DePuy Synthes Inc.; for their support. They did not receive compensation for this work.D. Revilla-Nebreda, 1 * M. Roncero-Riesco, 1 A. Santos-Briz, 2 M. Medina-Miguel añez, 1 N. Segurado-Tost on, 1 C. Rom an-Curto 1 1 Dermatology Department, Complejo Asistencial Universitario de Salamanca, Gerencia Regional de Salud de Castilla y Le on (SACYL), Salamanca, Spain, 2 Pathology Department, Complejo Asistencial Universitario de Salamanca, Gerencia Regional de Salud de Castilla y Le on (SACYL), Salamanca, Spain *Correspondence: D Revilla-Nebreda, E-mail: drevillan@saludcast illayleon.es